Skip to content

The effect of oral Crocus Sativus (Saffron) tablet on cervical ripening in pregnant women with gestational age of 39-41 weeks

The effect of oral Crocus Sativus (Saffron) tablet on cervical ripening in term pregnant women: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201212233706N19
Enrollment
50
Registered
2013-03-17
Start date
2013-03-27
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical ripening. Primary inadequate contractions

Interventions

Treatment - Drugs
Placebo
Intervention 1: Intervention group: Receiving 3 doses of oral 250 mg saffron tablets each 8 hours. Intervention 2: Control group: Receiving 3 doses of oral 250 mg placebo tablets each 8 hours.
Intervention group: Receiving 3 doses of oral 250 mg saffron tablets each 8 hours
Control group: Receiving 3 doses of oral 250 mg placebo tablets each 8 hours

Sponsors

Research deputy of Tabriz university of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 39 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Women with 1-3 gravidity and gestational age of 39-41 weeks 2. Not starting uterine contractions 3. Willing to deliver in Bonab hospital 4. Secondary and higher educational level 5. Bishop score of four or less 6. Singleton pregnancy 7. Cephalic presentation 8. Intact amniotic sac 9. Reactive non-stress test 10. Estimated fetal weight of 2500 to 4000 grams by ultrasound or examination. Exclusion criteria: 1. History of cryotherapy or cautery of the cervix 2. History of cesarean or having any indication for cesarean section in current pregnancy 3. Diagnosed fetal anomalies 4. Cephalo-Pelvic Disproportion 5. Any known placental problem (placenta previa, placental abruption, placental insufficiency) 6. Maternal infection and systemic chronic diseases, including respiratory diseases, cardio - vascular, endocrine and... 7. Using any of the following drugs by the woman (oral hypoglycemic agents and insulin, anticoagulants such as aspirin and Warfarin ,non steroidal -anti-inflammatory drugs such as ibuprofen and naproxen, herbal drugs and antihypertensives, benzodiazepines such as lorazepam and diazepam, barbiturates such as phenobarbital, narcotics, antidepressant, Alcohol) 8. Not access to telephone line

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Bishop score. Timepoint: Befor intervention, at the time of onset of uterin contractions, 10-12 and 20-24 hours after intervention or at the time of doing other treatment interventions. Method of measurement: The Bishop rating system.

Secondary

MeasureTime frame
Duration of the first stage of labor. Timepoint: After finishing the first stage of labor. Method of measurement: Patient record.;Interval of onset of uterine active contractions and starting intervention. Timepoint: In the 24 hours after starting intervention. Method of measurement: Patient and clinician report.;Duration of the second stage of labor (in minutes). Timepoint: After finishing the second stage of labor. Method of measurement: Observation and physical exam.;Need to induce labor. Timepoint: Between admission in delivery room and delivery. Method of measurement: According to hospital records.;Delivery type. Timepoint: After delivery. Method of measurement: According to hospital records.;Vaginal delivery in 24 hours after starting intervention. Timepoint: 24 hours after intervention. Method of measurement: According to hospital records.;Amount of hemorrhage. Timepoint: The time of admission in delivery room and 12 hours after delivery. Method of measurement: Hematocrit assessment.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSadi Roghaieh

Faculty of Nursing and Midwifery, Tabriz University of Medical Sciences

r.sadi65@gmail.com+98 41 1233 0190

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026